Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Risa Motai
Michi Sawabe
Shigenori Kadowaki
Eiichi Sasaki
Daisuke Nishikawa
Hidenori Suzuki
Shintaro Beppu
Hoshino Terada
Nobuhiro Hanai
机构：
[1] Aichi Cancer Center,Department of Head and Neck Surgery
[2] Aichi Cancer Center,Department of Medical Oncology
[3] Aichi Cancer Center,Department of Pathology and Molecular Diagnostics
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Head and neck cancer; EXTREME; Paclitaxel; Cetuximab; Platinum-refractory; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1188 / 1195
页数：7
相关论文
共 50 条
  • [31] Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma
    Adamo, V
    Ferraro, G
    Pergolizzi, S
    Sergi, C
    Laudani, A
    Settineri, N
    Alafaci, E
    Scimone, A
    Spano, F
    Spitaleri, G
    ORAL ONCOLOGY, 2004, 40 (05) : 525 - 531
  • [32] Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
    Ye, Dongmei
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [33] Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
    Tien-Hua Chen
    Yi-Ying Pan
    Tsung-Lun Lee
    Ling-Wei Wang
    Shyh-Kuan Tai
    Pen-Yuan Chu
    Wen-Liang Lo
    Cheng-Hsien Wu
    Muh-Hwa Yang
    Peter Mu-Hsin Chang
    BMC Cancer, 22
  • [34] Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
    Chen, Tien-Hua
    Pan, Yi-Ying
    Lee, Tsung-Lun
    Wang, Ling-Wei
    Tai, Shyh-Kuan
    Chu, Pen-Yuan
    Lo, Wen-Liang
    Wu, Cheng-Hsien
    Yang, Muh-Hwa
    Chang, Peter Mu-Hsin
    BMC CANCER, 2022, 22 (01)
  • [35] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Bernier, Jacques
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 705 - 713
  • [36] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Jacques Bernier
    Nature Clinical Practice Oncology, 2008, 5 : 705 - 713
  • [37] Cetuximab (CTX) Plus Platinum-Based Chemotherapy (CT) in Recurrent and Metastatic Head-and-Neck Squamous Cell Carcinoma (HN SCC): Our Extreme Experience Management of Recurrent Head-and-Neck Squamous Cell Carcinoma
    Costa, D.
    Gouveia, E.
    Mouta, J.
    Winckler, P.
    Esteves, S.
    Sargento, I.
    Ferreira, M.
    Moreira, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 509 - 509
  • [38] Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN).
    Kies, M. S.
    Garden, A. S.
    Holsinger, C.
    Papadimitrakopoulou, V.
    El-Naggar, A. K.
    Gillaspy, K.
    Lewin, J.
    Lu, C.
    Villalobos, S.
    Glisson, B. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [39] Retrospective study of weekly paclitaxel-cetuximab (WPC) in unselected patients (p) with recurrent/metastatic head and neck squamous cell carcinoma (RM-SCCHN)
    Pajares Bernad, I.
    Martinez Trufero, J.
    Calera Urquizu, L.
    Cebolleo de Miguel, A.
    Pazo Cid, R.
    Lanzuela Valero, M.
    Agsustin, M. J.
    Millastre, E.
    Santander Lobera, C.
    Alvarez Alejandro, M.
    Gimeno, N.
    Malo Yague, M.
    Llorente, Y.
    Anton Torres, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin, cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.
    Locke, Margaret
    Kohn, Nina
    Seetharamu, Nagashree
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18019 - E18019
12345